Industry Roundup: Mannatech, FTC On Lunada, Nutroganics, Vitamin Shoppe
This article was originally published in The Tan Sheet
Executive Summary
Mannatech rides Asia-Pacific growth; FTC disputes Lunada claims; Nutroganics sprouts profit; Vitamin Shoppe calms Oregon, Vermont on BMPEA; and more news in brief.
You may also be interested in...
GNC, Vitamin Shoppe Not On Same Page In Solving Similar Growth Challenges
Common thread between the manufacturers and retail chain operators offering their own and other brands extends to relatively recent executive suite shakeups following extended stretches of declining sales growth. GNC reported nearly $70m net income for 2018 after two years of net losses and Vitamin Shoppe trimmed its loss by more than $200m from 2017 to $12.1m.
In Brief
Appropriations subcommittee largely ignores FDA; analysts predict lower Novartis OTC sales; France tightens advertising rules; NAD weighs in on Lunada claims; Global Biotechnologies supplements seized; Tetley tea faces lawsuit for antioxidant claims; more news In Brief.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”